Gsk Share Discussion Threads

[alphorn] 13/4/2022 09:08

A blue sky guess - once the split has taken place the new pharma operation will take the opportunity to write down some of this capitalised 'R&D' following a 'strategic review' of its programmes. Otherwise these huge amounts will sit there as potential future costs.

[alibizzle] 13/4/2022 09:05

Is it worth buying now as seems high , I have around 40k to invest. And was going to keep it in till ex div date in may and hopefully cash out for around 18.50 plus dividend ? Thanks

[alphorn] 13/4/2022 09:00

A reminder that these acquisitions of, basically, R&D, go to the balance sheet, whereas if they were in-house R&D they would hit profits.

[anhar] 13/4/2022 08:50

Acquisition is a good move by GSK

Eh? $1.9bn acquisition, for cash, that presumably is being raised by further debt. Yet GSK was already imo crippled by excessive debt, even before this. This debt burden is one of the reasons for the relatively poor performance of GSK over the long term to date as shown by the chart above, the price is now about 20% below what it was 25 years ago! For the same reason divis have been unchanged for many years.

[smidge21] 13/4/2022 07:57

Updates can be sourced here (free)



create your own alert list

[tradermichael] 13/4/2022 07:01

Acquisition is a good move by GSK

[tradermichael] 13/4/2022 07:01

Its on ADVFN (for GSK Latest news) today

[ayl30] 13/4/2022 06:59

Today ?? Where did you see that?

[tradermichael] 13/4/2022 06:28

GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn

-- Sierra Oncology's differentiated momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia

-- Momelotinib complements GSK's existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022

-- Sales contribution expected to start in 2023 with significant growth potential thereafter
-- Supports development of strong portfolio of new specialty medicines and vaccines
GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion (GBP1.5 billion).

Myelofibrosis is a fatal cancer of the bone marrow impacting the normal production of blood cells. Anaemia represents a high unmet medical need in patients with myelofibrosis. At diagnosis, approximately 40% of patients are already anaemic, and it is estimated that nearly all patients will eventually develop anaemia.[1](,) [2] Patients treated with the most commonly used JAK inhibitor will often require transfusions, and more than 30% will discontinue treatment due to anaemia.[3] Anaemia and transfusion dependence are strongly correlated with poor prognosis and decreased overall survival.[4]

Momelotinib has a differentiated mode of action with inhibitory activity along key signalling pathways. This activity may lead to beneficial treatment effects on anaemia and reduce the need for transfusions while also treating symptoms. In January 2022, Sierra Oncology announced positive topline results from the MOMENTUM phase III trial. The study met all its primary and key secondary endpoints, demonstrating that momelotinib achieved a statistically significant and clinically meaningful benefit on symptoms, splenic response, and anaemia.

Luke Miels, Chief Commercial Officer, GSK said: "Sierra Oncology complements our commercial and medical expertise in haematology. Momelotinib offers a differentiated treatment option that could address the significant unmet medical needs of myelofibrosis patients with anaemia, the major reason patients discontinue treatment. With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty medicines."

[ayl30] 13/4/2022 06:15

Oncology aquisition

[tradermichael] 12/4/2022 11:43

GSK says:

The Consumer Healthcare segment will be reported as a "Continuing operation" operating segment until such time as the formal criteria for treating Consumer Healthcare as a 'Discontinued operation' have been satisfied (currently expected in Q2 2022). We will consolidate the business for reporting purposes until the demerger has completed.

[alphorn] 12/4/2022 11:17

GSK is back on my watch list.

Gateside - have you picked up the new name 'Glazo'? ;)

[tradermichael] 12/4/2022 10:34

GSK says:

The Consumer Healthcare segment will be reported as a "Continuing operation" operating segment until such time as the formal criteria for treating Consumer Healthcare as a 'Discontinued operation' have been satisfied (currently expected in Q2 2022). We will consolidate the business for reporting purposes until the demerger has completed.

[florenceorbis] 12/4/2022 10:02

Nice to see 1775p maintained

[florenceorbis] 12/4/2022 10:01

Targets Six months: 2086.98 One year: 2437.60

Supports Support1: 1575.81 Support2: 1445.40

Resistances Resistance1: 1786.80 Resistance2: 2086.98

The Market according to STOXLINE

[florenceorbis] 12/4/2022 09:56

Starting to look toppy but some think it has further to run

[tradermichael] 12/4/2022 09:18

I expect a continued uptick ahead of the quarterly earnings report in 2 weeks time (27 Apr 22) ..... ;0)

[alphorn] 12/4/2022 09:09

Closed out positions to take the gain. On watch list for any share price fall.

[netcurtains] 10/4/2022 11:01

British Bulls says stay long:


trading view says STRONG BUY

[andyadvfn1] 10/4/2022 10:49

Think it's not just a GSK doing well, the pharma sector is doing well, defensive play for the troubles ahead

[scootstephen] 10/4/2022 10:12

Would you buy more at these higher prices or just wait for the split ?

[tradermichael] 10/4/2022 09:18

tornado12 - I think the 'clear reason behind' the recovery is the positive response from the market to announcements and projections made by GSK on their proposed demerger/listing of the two businesses. That being the case, it might be prudent to wait for the 'split'. (Of course, its never wrong to take a profit!).

Good luck, TM

[zho] 09/4/2022 17:33

I've just read GSK's guidance for New GSK. They're targeting revenues of "£33 billion (CER) by 2031" with an improved "operating margin from the mid-20s% in 2021 to over 30% by 2026".

If they can deliver, then a mid to high teens multiple implies CAG in the share price of 8% for the next 10 years, plus dividends.

[tornado12] 09/4/2022 15:17

I am surprised by the recovery in the share price without clear reason behind. The question is whether to wait for the split and see if extra value arrives quickly or sell and take the good profits made. Difficult one to call for me at the moment as my original strategy was to wait until after the split...